Peaches Biotech participates in the 4D-BIOSKIN consortium for the production of human skin generated with a bioprinter
This regenerative medicine project will carry out the first clinical trial in Spain to treat burns and skin wounds with autologous bioprinted human skin substitutes.
Peaches Biotech, specialised in innovative treatments in regenerative medicine, is part of the 4D-BIOSKIN research consortium to create the first 3D bioprinted advanced skin therapy solution approved in Spain.
The development of this innovative therapy based on skin bioprinting is a potential therapeutic alternative for the treatment of burns and skin wounds that will have a major impact on society and the healthcare system. According to the OMS burns cause around 180,000 deaths annually.
The 4D-Bioskin Project covers the development and translation of autologous skin tissue manufacturing for clinical practice, using the first certified 3D bioprinter certified in Spain for the manufacture of bioprinted products for clinical use.
Peaches contributes to the development of autologous cell banks to provide the necessary quantities of keratinocytes and fibroblasts, key cells in the skin, as well as improving cell expansion and storage to minimise the time needed to obtain these cells. This optimisation aspect is key to industrialisation.
As a proof of concept of the product, a clinical trial will be carried out at the facilities of the Vall d'Hebron University Hospital -VHIR and the Hospital Universitario Virgen de la Arrixaca -FFIS on paediatric patients affected by burns who will be implanted with autologous skin substitutes. This ‘artificial skin’ will be manufactured with the first 3D bioprinter certified in Spain for the manufacture of bioprinted products for clinical use.